ES2337122B1 - CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. - Google Patents
CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. Download PDFInfo
- Publication number
- ES2337122B1 ES2337122B1 ES200802449A ES200802449A ES2337122B1 ES 2337122 B1 ES2337122 B1 ES 2337122B1 ES 200802449 A ES200802449 A ES 200802449A ES 200802449 A ES200802449 A ES 200802449A ES 2337122 B1 ES2337122 B1 ES 2337122B1
- Authority
- ES
- Spain
- Prior art keywords
- cytostatic
- compound
- oncolytic
- ethyl alcohol
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000019441 ethanol Nutrition 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 9
- 208000001840 Dandruff Diseases 0.000 claims abstract description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 6
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 6
- 210000004761 scalp Anatomy 0.000 claims abstract description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 6
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 3
- 239000000839 emulsion Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 24
- 230000001085 cytostatic effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000824 cytostatic agent Substances 0.000 claims description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 238000005360 mashing Methods 0.000 claims 1
- 208000014267 psoriasis 8 Diseases 0.000 claims 1
- 208000014235 psoriasis 9 Diseases 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 5
- 201000004681 Psoriasis Diseases 0.000 abstract description 4
- 208000009621 actinic keratosis Diseases 0.000 abstract description 4
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 2
- 208000001126 Keratosis Diseases 0.000 abstract description 2
- 238000002803 maceration Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract 3
- 244000274883 Urtica dioica Species 0.000 abstract 2
- 235000009108 Urtica dioica Nutrition 0.000 abstract 2
- 241000546188 Hypericum Species 0.000 abstract 1
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 1
- 240000007049 Juglans regia Species 0.000 abstract 1
- 235000009496 Juglans regia Nutrition 0.000 abstract 1
- 244000178231 Rosmarinus officinalis Species 0.000 abstract 1
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 235000014787 Vitis vinifera Nutrition 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000002532 grape seed extract Nutrition 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- 235000020234 walnut Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 12
- 208000004210 Pressure Ulcer Diseases 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuesto citoestático-oncolítico, procedimiento de obtención y uso externo e interno del mismo.Compound cytostatic-oncolytic, obtaining procedure and external and internal use of it.
Compuesto citoestático-oncolítíco a base de extractos de plantas y procedimiento para su obtención. El producto comprende una emulsión alcohólica de plantas secas, con la siguiente composición por cada 100 ml de alcohol etílico; 2-5 g de Vitis Vinifera, 2-5-6 g de romero, 2-5-6 g de hojas de nogal, 2-5-6 g de ortiga mayor y 2-5-6 g de ortiga menor y 2-5-6 g de hipérico.Compound cytostatic-oncolytic based on extracts of plants and procedure for obtaining them. The product comprises a alcoholic emulsion of dried plants, with the following composition per 100 ml of ethyl alcohol; 2-5 g of Vitis Vinifera, 2-5-6 g of rosemary, 2-5-6 g of walnut leaves, 2-5-6 g of nettle and 2-5-6 g of small nettle and 2-5-6 g of hypericum.
El procedimiento comprende someter a maceración a temperatura ambiente y con esporádica agitación una mezcla formada por el alcohol etílico y las cantidades mencionadas de las citadas plantas secas en un recipiente cerrado durante 7 a 14 días seguido de filtración del extracto resultante.The procedure includes subjecting to maceration at room temperature and with sporadic stirring a mixture formed by ethyl alcohol and the aforementioned amounts of those cited dried plants in a closed container for 7 to 14 days followed of filtration of the resulting extract.
Aplicación para el tratamiento y prevención de psoriasis interna y articular, carcinoma escamoso, queratosis actínica (queratosis solar), dermatitis seborreica del cuero cabelludo, caspa, dermatitis por contacto, dermatitis herpetiforme.Application for the treatment and prevention of internal and joint psoriasis, squamous carcinoma, keratosis actinic (solar keratosis), seborrheic skin dermatitis scalp, dandruff, contact dermatitis, dermatitis herpetiform
Description
Compuesto citoestático-oncolítico, procedimiento de obtención y uso externo e interno del mismo.Compound cytostatic-oncolytic, obtaining procedure and external and internal use of it.
La presente invención se encuentra en el campo técnico de los productos citoestáticos para el tratamiento y prevención del carcinoma escamoso, la queratosis actínica y de afecciones menos graves como dermatitis seborreica del cuerpo cabelludo, caspa, dermatitis por contacto, dermatitis herpetiforme.The present invention is in the field cytostatic products technician for treatment and prevention of squamous carcinoma, actinic keratosis and less serious conditions such as seborrheic body dermatitis scalp, dandruff, contact dermatitis, dermatitis herpetiform
De forma más concreta, la presente invención se refiere a un producto citoestático obtenido a partir de extractos de plantas.More specifically, the present invention will be refers to a cytostatic product obtained from extracts of plants.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La carencia de fármacos eficaces contra las escaras canceradas impone que, en su defecto, se tengan que emplear los métodos quirúrgicos más drásticos.The lack of effective drugs against Canceled bedsores require that, failing that, they have to be used the most drastic surgical methods.
Se han buscado fármacos para estos tratamientos, pero hasta la fecha no se ha conseguido encontrar productos suficientemente efectivos.Drugs have been sought for these treatments, but to date it has not been possible to find products sufficiently effective.
Según informa el Vademecum Internacional, existen fármacos contra las escaras de postración o decúbito pero no para las escaras canceradas. En dicha publicación puede observarse que tanto en el apartado que dedica a "citoestáticos" antimetabolitos, como en otro que titula "Cáncer (tratamiento paliativo)" solo aparece un fármaco para aplicación tópica en pomada llamado Efudix (de Laboratorios Roche) que contienen como principio activo 5-fluorouracilo al 5% en forma de suspensión en una base emulsionada de aceite/agua.As reported by the Vademecum International, there are drugs against bedsores or recumbency but not for canceled bedsores. In this publication you can see that both in the section dedicated to "cytostatics" antimetabolites, as in another titled "Cancer (treatment palliative) "only one drug appears for topical application in ointment called Efudix (from Roche Laboratories) that contain as 5-fluorouracil 5% active substance in the form of suspension in an emulsified oil / water base.
Por sus propiedades citoestáticas, este fármaco está indicado para ciertas alteraciones cutáneas preneoplásicas y neoplásicas queratosis solar y queratosis senil, enfermedad de Bowen, así como epiteliomas basocelulares superficiales simples o múltiples. El producto se aplica en forma de capa fina con o sin vendaje oclusivo, dependiendo del tipo de afección y, como casi todos los fármacos, está contraindicado en caso de embarazo o hipersensibilidad al principio activo.Due to its cytostatic properties, this drug It is indicated for certain preneoplastic skin disorders and Neoplastic solar keratosis and senile keratosis disease Bowen, as well as simple superficial basal cell epitheliomas or multiple. The product is applied as a thin layer with or without occlusive bandage, depending on the type of condition and, as almost All drugs are contraindicated in case of pregnancy or hypersensitivity to the active substance.
En cuanto a los efectos secundarios de este producto, puede mencionarse el enrojecimiento e irritación de la piel adyacente a la lesión tratada, si bien esto cede rápidamente al suspender el tratamiento.As for the side effects of this product, the redness and irritation of the skin adjacent to the treated lesion, although this quickly yields to the stop treatment
Por lo tanto aún sigue siendo necesario la búsqueda de nuevos productos con mayor campo de aplicación y menos efectos secundarios al tiempo que presenten una buena tolerancia, con el fin de evitar en la mayor medida posible los métodos quirúrgicos.Therefore, the search for new products with greater scope and less side effects while presenting a good tolerance, in order to avoid as much as possible the methods Surgical
En esta linea, la presente invención proporciona un producto citoestático que sorprendentemente ha permitido el tratamiento y curación de dolencias del tipo de las mencionadas en personas que tenían que someterse regularmente a intervenciones de electrocisión, por no existir en el mercado ningún fármaco capaz de controlar y/o curar su dolencia.In this line, the present invention provides a cytostatic product that has surprisingly allowed the treatment and cure of ailments of the type mentioned in people who had to regularly undergo interventions of electrocision, because there is no drug capable of control and / or cure your medical condition
El producto de la presente invención presenta además una excelente tolerancia y no se tiene noticia de pacientes sensibles a su composición. Si bien no se han efectuado pruebas en embarazadas, cabe suponer que, dada la composición del producto, tampoco haya ningún tipo de problema.The product of the present invention presents also excellent tolerance and there is no patient news sensitive to its composition. While no tests have been performed on pregnant women, it is assumed that, given the composition of the product, There is also no problem.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La presente invención, tal y como se indica en su enunciado, se refiere a un producto citoestático-oncolítico a base de extractos de plantas y al procedimiento para su obtención.The present invention, as indicated in Your statement refers to a product cytostatic-oncolytic based on extracts of plants and the procedure for obtaining them.
De forma más concreta, la presente invención se refiere a un producto citoestático-oncolítico, resolutivo de las escaras canceradas resultantes del carcinoma escamoso y/o las queratosis actínicas, el cual evita las terapias más agresivas en esta fase de la enfermedad, tales como los métodos quirúrgicos más drásticos (electrocisión) y prácticamente imprescindibles en el estado actual de la técnica. El producto permite además el adecuado tratamiento de afecciones comparativamente menos graves, tales como dermatitis seborreica del cuerpo cabelludo, caspa, dermatitis por contacto, dermatitis herpetiforme.More specifically, the present invention will be refers to a cytostatic-oncolytic product, Resolution of cancerous bedsores resulting from carcinoma squamous and / or actinic keratosis, which avoids therapies more aggressive in this phase of the disease, such as methods more drastic surgical (electrocision) and practically essential in the current state of the art. The product also allows the proper treatment of conditions comparatively less severe, such as seborrheic dermatitis of the scalp, dandruff, contact dermatitis, dermatitis herpetiform
Asimismo, dado que es un medicamento apto para ingerir, es apto también para el tratamiento de la psoriasis interna o articular.Also, since it is a drug suitable for ingest, is also suitable for the treatment of internal psoriasis or articulate
\newpage\ newpage
El producto citoestático-oncolítico de la invención se caracteriza por ser una emulsión alcohólica de plantas secas, con la siguiente composición por cada 100 ml de alcohol etílico:The product cytostatic-oncolytic of the invention is characterized by being an alcoholic emulsion of dried plants, with the following composition per 100 ml of ethyl alcohol:
El alcohol etílico empleado es alcohol etílico de 70 a 96º, o bien alcohol de boca.The ethyl alcohol used is ethyl alcohol from 70 to 96º, or mouth alcohol.
El procedimiento para la obtención de este producto citoestático-oncolítico comprende someter a maceración a temperatura ambiente y con esporádica agitación una mezcla formada por el alcohol etílico, de 70 a 96º o bien alcohol de boca, y las cantidades mencionadas de las citadas plantas secas en un recipiente cerrado durante 7 a 14 días. Transcurrido ese tiempo se filtra el extracto deseado para separarlo de los restos de las plantas y se embotella para su posterior almacenamiento.The procedure for obtaining this cytostatic-oncolytic product comprises subjecting maceration at room temperature and with sporadic agitation a mixture formed by ethyl alcohol, 70 to 96º or alcohol of mouth, and the mentioned amounts of the mentioned dried plants in a closed container for 7 to 14 days. After that time the desired extract is filtered to separate it from the remains of the plants and bottled for later storage.
Una realización de la invención es el uso del compuesto citoestático-oncolítico para la fabricación de un medicamento por vía oral para el tratamiento de la psoriasis interna, y una realización más preferente es que sea para el tratamiento de la psoriasis articular.An embodiment of the invention is the use of cytostatic-oncolytic compound for manufacture of an oral medication for the treatment of internal psoriasis, and a more preferred embodiment is for The treatment of joint psoriasis.
Otra realización más es su uso en la fabricación de un medicamento para el tratamiento de afecciones de la piel de tipo canceroso con escaras, en cuyo caso se aplica dicho medicamento por vía tópica de la siguiente forma:Another embodiment is its use in manufacturing of a medication for the treatment of skin conditions of cancerous type with bedsores, in which case such medication is applied topically as follows:
- como resolutivo: se aplican directamente sobre las escaras 2 ó 3 gotas del medicamento, en función de la extensión o tamaño de la lesión, al menos 2 veces al día, no siendo necesario vendaje oclusivo (incluso se han obtenido resultados positivos con una sola aplicación diaria, aunque lo habitual sean dos);- as operative: they apply directly to the bedsores 2 or 3 drops of the medicine, depending on the extension or size of the lesion, at least 2 times a day, not being necessary occlusive bandage (positive results have even been obtained with a single daily application, although usual two);
- como preventivo-regenerador: se aplica una fricción diaria del medicamento que abarque tanto la zona afectada como sus inmediaciones.- as preventive-regenerator: a daily friction of the medicine that covers both the Affected area as its surroundings.
Ha podido observarse que en el transcurso de unas semanas de tratamiento, tres o cuatro normalmente, se desprenden las escaras canceradas sin producirse dolor ni erosionarse lo más mínimo la piel que servía de base ni la circundante.It has been observed that in the course of A few weeks of treatment, three or four normally, will detach the canceled bedsores without causing pain or erode the skin that was the basis or the least surrounding.
Por ello el medicamento fabricado con el producto de la presente invención se puede aplicar también en las zonas circundantes de dichas afecciones de la piel de tipo canceroso con escaras para evitar la formación de neoplasmas que posteriormente podrían pasar a ser carcinomas escamosos.Therefore the medicine manufactured with the product of the present invention can also be applied in the surrounding areas of such cancerous skin conditions with bedsores to prevent the formation of neoplasms that subsequently they could become squamous carcinomas.
De forma que otra realización preferente de la presente invención es su uso en la fabricación de un medicamento para el tratamiento del carcinoma escamoso.So that another preferred embodiment of the Present invention is its use in the manufacture of a medicament for the treatment of squamous carcinoma.
Las personas que se han tratado y curado con un medicamento fabricado con el producto de la invención afirman que otros medicamentos que se habían aplicado anteriormente nunca habían resultado efectivos y, consecuentemente, por lo general, se veían obligados a ser sometidos periódicamente a electrocisión (una intervención cada seis meses por término medio).People who have been treated and cured with a medicament manufactured with the product of the invention claim that other medications that had been previously applied had never effective results and, consequently, they usually looked forced to be periodically subjected to electrocision (a intervention every six months on average).
En definitiva, el medicamento fabricado con el producto de la invención actúa como resolutivo y regenerador sin producir efectos secundarios negativos aunque se emplee como preventivo durante años. Aparte de sus propiedades regenerativas y estabilizadoras de la piel es posible incluso tomarlo en infusiones o diluirlo en agua y tratar rápidamente afecciones como diarreas, colitis, hemorroides agudas, inflaciones intestinales y desequilibrios hemoestáticos.In short, the medicine manufactured with the product of the invention acts as a resolver and regenerator without produce negative side effects even if used as preventive for years. Apart from its regenerative properties and skin stabilizers it is even possible to take it in infusions or dilute it in water and quickly treat conditions such as diarrhea, colitis, acute hemorrhoids, intestinal and hemostatic imbalances.
Para el tratamiento de afecciones menos graves tales como la dermatitis seborreica del cuero cabelludo, caspa, dermatitis por contacto, dermatitis herpetiforme, etc. el medicamento fabricado con el producto de la invención se aplica igualmente de forma tópica sobre la zona afectada, pero a concentraciones menores y distanciando las aplicaciones. Así por ejemplo, para la dermatitis seborreica del cuero cabelludo puede emplearse dicho medicamento a una concentración del 60% en alcohol etílico de 700, efectuando una aplicación diaria durante una semana mediante fricción con los dedos reduciendo después a una aplicación semanal durante un mes, siendo suficiente para el mantenimiento con una aplicación mensual. La caspa puede tratarse de la misma forma que la dermatitis seborreica, pero para el adecuado mantenimiento suelen ser necesarias dos aplicaciones mensuales.For the treatment of less serious conditions such as seborrheic dermatitis of the scalp, dandruff, contact dermatitis, herpetiform dermatitis, etc. he medicament manufactured with the product of the invention is applied also topically on the affected area, but at lower concentrations and distancing applications. So by example, for seborrheic dermatitis of the scalp you can use said medication at a concentration of 60% in alcohol Ethyl 700, making a daily application for a week by friction with the fingers then reducing to one application weekly for a month, being sufficient for maintenance with A monthly application. Dandruff can be treated the same way than seborrheic dermatitis, but for proper maintenance two applications are usually required monthly.
Por su parte, el tratamiento de la dermatitis por contacto depende de la extensión y gravedad de la misma. Por ejemplo, en el caso de las dermatitis producidas por los pendientes, se frota la zona afectada con un algodón ligeramente humedecido con el medicamento fabricado con el producto de la invención y después se aplican una o dos gotas en cada lóbulo afectado dejándolo secar, dos veces al día. La duración normal del tratamiento suele ser de uno o dos días.For its part, the treatment of dermatitis by contact depends on the extent and severity of it. By For example, in the case of dermatitis caused by earrings, rub the affected area with a slightly damp cotton with the medicament manufactured with the product of the invention and then one or two drops are applied to each affected lobe, letting it dry, twice daily. The normal duration of treatment is usually one or two days
En el caso de la dermatitis herpetiforme, sí se detecta prontamente su aparición y suponiendo que la zona afectada sean los labios, se puede seguir el mismo tratamiento que para la dermatitis por contacto pero con una duración de tres o cinco días.In the case of dermatitis herpetiformis, it does promptly detect its appearance and assuming that the affected area be the lips, you can follow the same treatment as for contact dermatitis but lasting three or five days.
La presente invención se ilustra adicionalmente mediante los siguientes ejemplos, en ningún modo limitativos de su alcance.The present invention is further illustrated. by the following examples, in no way limiting their scope.
Se obtuvo una formulación del producto de la invención a partir de la siguiente composición por cada 100 ml de alcohol etílico de 96º.A formulation of the product of the invention from the following composition per 100 ml of 96º ethyl alcohol.
En un recipiente se introdujeron 100 ml de etanol a 96º y se añadieron las proporciones indicadas de las plantas secas mencionadas. El recipiente se cerró y se mantuvo a temperatura ambiente durante 14 días agitándolo unos segundos cada día para favorecer el mezclado.100 ml of ethanol at 96 ° and the indicated proportions of the Dry plants mentioned. The container was closed and held at room temperature for 14 days shaking it a few seconds every day to favor mixing.
Transcurrido este tiempo, el extracto etanólico obtenido se filtró y embotelló para su posterior utilización.After this time, the ethanolic extract obtained was filtered and bottled for later use.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200802449A ES2337122B1 (en) | 2008-08-18 | 2008-08-18 | CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200802449A ES2337122B1 (en) | 2008-08-18 | 2008-08-18 | CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2337122A1 ES2337122A1 (en) | 2010-04-20 |
| ES2337122B1 true ES2337122B1 (en) | 2011-01-28 |
Family
ID=42074571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200802449A Expired - Fee Related ES2337122B1 (en) | 2008-08-18 | 2008-08-18 | CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2337122B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013015665A1 (en) * | 2011-07-25 | 2013-01-31 | Aguilar Sanchez Jose Luis | Formulation based on an extract of medicinal plants, coal tar pitch and salicylic acid for the effective control of psoriasis, method for obtaining said extract and forms of administration of the formulation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD109510A1 (en) * | 1974-02-04 | 1974-11-12 | ||
| ES2010103A6 (en) * | 1989-01-26 | 1989-10-16 | Jimenez Herranz Asuncion Palom | Tonic lotion for correcting skin acidity |
| ES2056031A1 (en) * | 1993-03-10 | 1994-09-16 | Martin Vicente Juan Aparisi | New cytostatic-scaricide product based on plant extracts and procedure for obtaining it |
| JPH11240842A (en) * | 1998-02-24 | 1999-09-07 | Shiseido Co Ltd | Protease inhibitor |
| RO120529B1 (en) * | 2002-05-13 | 2006-03-30 | Institutul De Tehnologie Chimică - Itec S.A. | Antioxidant composition based on natural extracts for treating psoriasis |
| WO2007137602A1 (en) * | 2006-05-29 | 2007-12-06 | Patent Engineering Trust Reg. | Method of producing a liquid oral or otherwise applicable composition for administration to human beings and animals, liquid oral or otherwise applicable composition and its use of the composition for the manufacture of a product for functional nutrition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8708116A1 (en) * | 1986-05-20 | 1987-07-16 | Jorques Cataluna J Antonio | Prepn. for preventing hair loss |
-
2008
- 2008-08-18 ES ES200802449A patent/ES2337122B1/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD109510A1 (en) * | 1974-02-04 | 1974-11-12 | ||
| ES2010103A6 (en) * | 1989-01-26 | 1989-10-16 | Jimenez Herranz Asuncion Palom | Tonic lotion for correcting skin acidity |
| ES2056031A1 (en) * | 1993-03-10 | 1994-09-16 | Martin Vicente Juan Aparisi | New cytostatic-scaricide product based on plant extracts and procedure for obtaining it |
| JPH11240842A (en) * | 1998-02-24 | 1999-09-07 | Shiseido Co Ltd | Protease inhibitor |
| RO120529B1 (en) * | 2002-05-13 | 2006-03-30 | Institutul De Tehnologie Chimică - Itec S.A. | Antioxidant composition based on natural extracts for treating psoriasis |
| WO2007137602A1 (en) * | 2006-05-29 | 2007-12-06 | Patent Engineering Trust Reg. | Method of producing a liquid oral or otherwise applicable composition for administration to human beings and animals, liquid oral or otherwise applicable composition and its use of the composition for the manufacture of a product for functional nutrition |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2337122A1 (en) | 2010-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2278393T3 (en) | ANTIMICROBIAL TREATMENT OF VIRUS HERPES SIMPLEX AND OTHER INFECTIOUS DISEASES. | |
| ES2206195T3 (en) | PHARMACEUTICAL PRODUCTS, FOOD SUPPLEMENTS AND COSMETIC COMPOSITIONS THAT INCLUDE A FAT AND GINGER ACID. | |
| ES2600909T3 (en) | Compositions containing berberine or analogues thereof to treat rosacea or skin disorders related to redness of the face | |
| WO2008140200A1 (en) | External compositions for the skin | |
| CN102440929B (en) | Compound wild chrysanthemum spraying agent | |
| US20170258861A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
| ES2221176T3 (en) | USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR QUICK RELIEF OF PICOR OR LOCATED PAIN. | |
| KR102220534B1 (en) | Soothing cream and manufacturing method for the same | |
| EP2983684B1 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations | |
| ES2337122B1 (en) | CYTOSTATIC-ONCOLITICAL COMPOUND, PROCEDURE FOR OBTAINING AND EXTERNAL AND INTERNAL USE OF THE SAME. | |
| ES2394316T3 (en) | Pharmaceutical compositions of Carapa Guianensis. | |
| WO2016054757A1 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, camomile and propolis | |
| WO2020111621A1 (en) | Composition for inhibiting hair loss or skin inflammation | |
| CN105012487A (en) | Bishutong nasal drops for children | |
| CN105193898A (en) | Rhodiola kirilowii(Regel)Maxim extract and application thereof in cosmetics | |
| CN116602879A (en) | A mite-removing composition, a mite-removing additive containing the same, preparation method and application thereof | |
| CN108420781A (en) | A kind of toothpaste | |
| RU2282473C2 (en) | Curative-prophylactic pomade eliciting antiviral activity and method for its preparing | |
| ES2581180B1 (en) | USE OF ORAL ALOE FOR HAIR IMPROVEMENT | |
| CN105106080A (en) | Chinese herbal medicine mask and preparation method thereof | |
| TWI814490B (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for burn wound therapy | |
| KR102790058B1 (en) | Composition for preventing, ameliorating or treating rosacea comprising Artemisia sp. plant extracts as an active ingredient | |
| BRPI1002720B1 (en) | USE OF A VEGETABLE EXTRACT | |
| ES2382845B2 (en) | IMPROVEMENTS INTRODUCED IN THE MAIN PATENT P200400524 FOR "NATURAL LIQUID COMPOSITION AGAINST INFECTIONS". | |
| ES2926475T3 (en) | Neem for the treatment of RLS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20100420 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2337122 Country of ref document: ES Kind code of ref document: B1 Effective date: 20110118 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180924 |